These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21570843)

  • 1. Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.
    Li RD; Zhang X; Li QY; Ge ZM; Li RT
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3637-40. PubMed ID: 21570843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel dithiocarbamic acid esters derived from 6-aminomethyl-4-anilinoquinazolines and 6-aminomethyl-4-anilino-3-cyanoquinolines as potent EGFR inhibitors.
    Zhang X; Li R; Qiao K; Ge Z; Zhang L; Cheng T; Li R
    Arch Pharm (Weinheim); 2013 Jan; 346(1):44-52. PubMed ID: 23180607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
    Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
    Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
    Rao GW; Xu GJ; Wang J; Jiang XL; Li HB
    ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects.
    Antonello A; Tarozzi A; Morroni F; Cavalli A; Rosini M; Hrelia P; Bolognesi ML; Melchiorre C
    J Med Chem; 2006 Nov; 49(23):6642-5. PubMed ID: 17154492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
    Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
    Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
    Xu YY; Li SN; Yu GJ; Hu QH; Li HQ
    Bioorg Med Chem; 2013 Oct; 21(19):6084-91. PubMed ID: 23962660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
    Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
    J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
    Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
    Klutchko SR; Zhou H; Winters RT; Tran TP; Bridges AJ; Althaus IW; Amato DM; Elliott WL; Ellis PA; Meade MA; Roberts BJ; Fry DW; Gonzales AJ; Harvey PJ; Nelson JM; Sherwood V; Han HK; Pace G; Smaill JB; Denny WA; Showalter HD
    J Med Chem; 2006 Feb; 49(4):1475-85. PubMed ID: 16480284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
    Carmi C; Cavazzoni A; Vezzosi S; Bordi F; Vacondio F; Silva C; Rivara S; Lodola A; Alfieri RR; La Monica S; Galetti M; Ardizzoni A; Petronini PG; Mor M
    J Med Chem; 2010 Mar; 53(5):2038-50. PubMed ID: 20151670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.
    El Ella DA; Saleh KA; Hassan M; Hamdy N; El-Araby ME; Abouzid KA
    Arzneimittelforschung; 2012 Aug; 62(8):360-6. PubMed ID: 22723174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
    Ballard P; Bradbury RH; Harris CS; Hennequin LF; Hickinson M; Johnson PD; Kettle JG; Klinowska T; Leach AG; Morgentin R; Pass M; Ogilvie DJ; Olivier A; Warin N; Williams EJ
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1633-7. PubMed ID: 16380259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
    Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study.
    El-Azab AS; Al-Omar MA; Abdel-Aziz AA; Abdel-Aziz NI; el-Sayed MA; Aleisa AM; Sayed-Ahmed MM; Abdel-Hamide SG
    Eur J Med Chem; 2010 Sep; 45(9):4188-98. PubMed ID: 20599299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
    Zuo SJ; Zhang S; Mao S; Xie XX; Xiao X; Xin MH; Xuan W; He YY; Cao YX; Zhang SQ
    Bioorg Med Chem; 2016 Jan; 24(2):179-90. PubMed ID: 26706113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
    Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
    Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.